| 25.01 0.69 (2.84%) | 08-05 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 30.26 | 1-year : | 32.64 |
| Resists | First : | 25.91 | Second : | 27.95 |
| Pivot price | 24.16  |
|||
| Supports | First : | 22.61 | Second : | 18.81 |
| MAs | MA(5) : | 24.09 |
MA(20) : | 24.79 |
| MA(100) : | 28.35 |
MA(250) : | 33.55 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.8 |
| %K %D | K(14,3) : | 42.9 |
D(3) : | 30.2 |
| RSI | RSI(14): 49 |
|||
| 52-week | High : | 47.31 | Low : | 22.61 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ VCYT ] has closed below upper band by 18.9%. Bollinger Bands are 31.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 25.11 - 25.21 | 25.21 - 25.32 |
| Low: | 23.95 - 24.05 | 24.05 - 24.16 |
| Close: | 24.84 - 25.02 | 25.02 - 25.21 |
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Tue, 05 Aug 2025
Veracyte Inc (VCYT) Q2 2025 Earnings Report Preview: What to Look For - Yahoo Finance
Mon, 28 Jul 2025
Veracyte (VCYT) Soars 7% on S&P SmallCap 600 Inclusion - MSN
Mon, 28 Jul 2025
Veracyte (VCYT) Soars 7.0%: Is Further Upside Left in the Stock? - Yahoo Finance
Sat, 26 Jul 2025
Veracyte (VCYT) Soars 7% on S&P SmallCap 600 Inclusion - ca.finance.yahoo.com
Fri, 25 Jul 2025
Veracyte to Join S&P SmallCap 600 Index in July 2025 - AInvest
Thu, 24 Jul 2025
Veracyte Secures Major Index Upgrade: Latest Healthcare Addition to S&P SmallCap 600 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 78 (M) |
| Shares Float | 78 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 107.9 (%) |
| Shares Short | 6,110 (K) |
| Shares Short P.Month | 5,940 (K) |
| EPS | 0.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 15.26 |
| Profit Margin | 7.1 % |
| Operating Margin | 7 % |
| Return on Assets (ttm) | 1.9 % |
| Return on Equity (ttm) | 2.8 % |
| Qtrly Rev. Growth | 18.2 % |
| Gross Profit (p.s.) | 4.16 |
| Sales Per Share | 5.91 |
| EBITDA (p.s.) | 0.79 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 89 (M) |
| Levered Free Cash Flow | 77 (M) |
| PE Ratio | 59.54 |
| PEG Ratio | 0 |
| Price to Book value | 1.63 |
| Price to Sales | 4.22 |
| Price to Cash Flow | 21.9 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|